Clik here to view.
Takeda Receives European Commission Approval of ADCETRIS® (brentuximab...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC) has extended the current conditional marketing authorization...
View ArticleClik here to view.
Cardiovascular Systems Submits Diamondback 360® Coronary Orbital Atherectomy...
ST. PAUL, Minn. Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), today announced that it has submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of...
View ArticleClik here to view.
武田薬品が日本で新規の経口プロテアソーム阻害薬イキサゾミブの製造販売承認申請を実施
大阪 武田薬品工業株式会社（TSE: 4502）は本日、厚生労働省にイキサゾミブの製造販売承認申請（NDA）を行ったと発表しました。イキサゾミブは、再発性もしくは難治性の多発性骨髄腫を治療するための初の経口プロテアソーム阻害薬です。...
View ArticleClik here to view.
Mitsubishi Heavy Industries Machine Tool Completes Delivery of 1st ABLASER...
TOKYO Mitsubishi Heavy Industries Machine Tool Co., Ltd., a Group company of Mitsubishi Heavy Industries, Ltd. (MHI)(TOKYO:7011), has completed delivery of its very first “ABLASER” laser...
View ArticleClik here to view.
欧盟委员会核准武田的ADCETRIS® (brentuximab vedotin)用于移植后霍奇金淋巴瘤巩固治疗
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE: 4502)今天宣布，欧盟委员会(EC)已延长了现有的ADCETRIS® (brentuximab vedotin)条件性营销授权，并核准ADCETRIS用于治疗自体干细胞移植(ASCT)后复发或进展风险增高的成人CD30+霍奇金淋巴瘤患者。在该决定之前，人用药品委员会于2016年5月26日发表了一项肯定意见。...
View ArticleClik here to view.
One of the World’s Leading Centers for Cardiovascular Medicine &...
NEUCHÂTEL, Switzerland Masimo (NASDAQ: MASI) announced today that Deutsches Herzzentrum Berlin (DHZB / German Heart Center Berlin) in Berlin, Germany, has adopted Masimo’s SedLine® Brain Function...
View ArticleClik here to view.
Diaverum and Yueda Group Sign Joint Venture Agreement to Operate Dialysis...
MUNICH & BEIJING Diaverum, one of the leading renal care providers worldwide, and the Chinese Yueda Group, a large state-owned enterprise group with multiple public listed companies based in...
View ArticleClik here to view.
世界领先的心血管医学及移植中心之一采用Masimo的SedLine®脑功能监护仪和O3™局部氧饱和度仪
瑞士纳沙泰尔 (美国商业资讯) — Masimo (NASDAQ: MASI)今天宣布，德国柏林的德国柏林心脏中心(Deutsches Herzzentrum Berlin, DHZB)已采用Masimo的SedLine®脑功能监护仪和O3™局部氧饱和度仪技术来监护手术室和重症监护病房中的患者。 Smart News Releases（智能新闻稿）是一个多媒体平台。在此处查看完整新闻稿：...
View ArticleClik here to view.
武田薬品、移植後のホジキンリンパ腫に対する地固め療法としてのアドセトリス（ブレンツキシマブ・ベドチン）に関して欧州委員会から承認を取得
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:...
View ArticleClik here to view.
世界有数の循環器医療／移植センターがマシモのSedLine®脳機能モニタリング技術とO3™リージョナルオキシメトリー技術を採用
スイス・ヌーシャテル （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、独ベルリンのドイツベルリン心臓センター（DHZB）が、手術室と集中治療室で患者をモニタリングするため、マシモのSedLine®脳機能モニタリング技術とO3™リージョナルオキシメトリー技術を採用したと発表しました。 このSmart News...
View ArticleClik here to view.
サンバイオ、米国における外傷性脳損傷を対象としたフェーズ２臨床試験の被験者組み入れ開始のお知らせ
米国カリフォルニア州マウンテンビュー （ビジネスワイヤ） — 神経系疾患を対象に再生細胞薬の開発・製造を手掛ける当社グループ（サンバイオ株式会社及びその子会社であるSanBio, Inc.）...
View ArticleClik here to view.
Nichi-Iko Pharmaceutical Co., Ltd to Acquire Sagent Pharmaceuticals for...
TOKYO & SCHAUMBURG, Ill. Nichi-Iko Pharmaceutical Co., Ltd (TSE:4541) and Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) today announced that they have entered into a definitive merger agreement...
View ArticleClik here to view.
Presbia to Participate in the 2016 Australasian Society of Cataract and...
DUBLIN Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced that it will participate in the 20th Annual Australasian Society of Cataract and...
View ArticleClik here to view.
First Patient is Randomized in STEMTRA Trial For Traumatic Brain Injury
MOUNTAIN VIEW, Calif. SanBio, Inc., a scientific leader in regenerative medicine for neurological disorders, today announced the randomization of the first patient in the STEMTRA Phase 2 clinical...
View ArticleClik here to view.
Dr. Reddy’s to Release Q1 FY17 Results on July 26, 2016 Earnings Call Slated...
HYDERABAD, India Dr. Reddy’s Laboratories (NYSE: RDY | NSE: DRREDDY | BSE: 500124) will announce results for the First Quarter ended June 30, 2016 on Tuesday, July 26, 2016 after the Board Meeting....
View ArticleClik here to view.
投资于癌症治愈方法：GE凭借收购Biosafe Group SA，致力于引领细胞疗法行业的产业化
英格兰CHALFONT ST GILES (美国商业资讯) — GE医疗集团已收购了Biosafe Group SA，后者是面向快速生长细胞疗法和再生医学行业的整合型细胞生物处理系统的提供商，该收购的金额未披露。收购Biosafe可壮大GE医疗集团面向细胞疗法客户的产品、解决方案和服务的端到端生态系统，并将GE的技术触角延伸到若干新的细胞和治疗类别。 Smart News...
View ArticleClik here to view.
Samsung Bioepis’ Marketing Authorization Application for SB5 Adalimumab...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency (EMA) has accepted for review the company’s Marketing Authorization Application (MAA) for SB5, a...
View ArticleClik here to view.
Increase of Myopia and Ageing Population Will Boost Global Eyewear Sales to...
SINGAPORE Market Research Company Euromonitor International released today new data on the global eyewear industry. According to the new research, global sales of eyewear are forecast to reach...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Announces the Launch of Omeprazole and Sodium...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Omeprazole and Sodium bicarbonate capsules,...
View ArticleClik here to view.
Kiwi Investors Help Launch Global Digital Health Company
HAMILTON, New Zealand A network of New Zealand angel investors has helped launch iPug, a digital health company that is transforming the way research and public health campaigns are delivered, into...
View Article